Skip to content

Advertisement

Antimicrobial Resistance & Infection Control

What do you think about BMC? Take part in

Open Access

Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in the intensive care unit

Antimicrobial Resistance & Infection Control20176:102

https://doi.org/10.1186/s13756-017-0256-2

Received: 22 May 2017

Accepted: 4 September 2017

Published: 2 October 2017

Abstract

Background

To analyze the clinical characteristics and outcomes of carbapenem-resistant Klebsiella pneumoniae (CRKp) and carbapenem-susceptible K. pneumoniae (CSKp) bloodstream infections (BSIs), and to study the risk factors for development of CRKp BSI and K. pneumoniae BSI-related mortality.

Methods

A retrospective case control study of patients with K. pneumoniae BSI was conducted in the intensive care unit of the First Affiliated Hospital, Medical of College, Zhejiang University from January 2013 to December 2014. Carbapenem resistance was defined in accordance with the Clinical and Laboratory Standards Institute 2016 guidelines. Risk factors for the development of CRKp BSI and risk factors for mortality due to K. pneumoniae BSI were assessed. Virulence genes were detected by polymerase chain reaction assay.

Results

In total, 48 patients were enrolled in the study, including 31 (65%) patients with CRKp BSI and 17 (35%) patients with CSKp BSI. CSKp infection was associated with more severe clinical symptoms, particularly a higher serum creatinine level (165.06 ± 127.01 in the CSKp group vs. 93.77 ± 84.35 μmol/L in the CRKp group, p = 0.039), but there was no significant difference in prognosis between the CSKp and CRKp groups. On multivariate analysis, indwelling central venous catheter (p = 0.045) was the only factor independently associated with CRKp bacteremia. However, the mortality of K. pneumoniae BSI patients was not correlated with carbapenem resistance. In addition, the isolates had diverse clonality and different origins. The frequency of detection of the allS and magA virulence genes was higher in the CSKp group than in the CRKp group (alls p = 0.04; magA p = 0.047).

Conclusions

Patients in the CSKp group experienced more severe clinical symptoms, although mortality did not differ significantly between the CRKp and CSKp groups. An indwelling central venous catheter was the only factor independently associated with CRKp BSI. The mortality of patients with K. pneumoniae BSI was not associated with carbapenem resistance. The frequency of virulence genes was higher in the CSKp group than in the CRKp group.

Background

Klebsiella pneumoniae, a member of the family Enterobacteriaceae, is a causative organism of various infections, including serious community-onset infections, such as necrotizing pneumonia, pyogenic liver abscesses, and endogenous endophthalmitis [1, 2]; and nosocomial infections, particularly urinary tract infections (UTIs), respiratory tract infections, and bloodstream infections (BSIs) [1, 3, 4]. Due to abuse of antimicrobial agents in developing countries, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) is of considerable concern. K. pneumoniae is the most prevalent Enterobacteriaceae species, accounting for 71.9% of 242 CRE strains in a retrospective study conducted in a tertiary hospital in Hangzhou, China [5]. Surveillance of antibiotic resistance by the China CHINET showed that 2.9% and 2.8% of Klebsiella spp. were resistant to imipenem and meropenem, respectively, in 2005 compared to 10.5% and 13.4%, respectively, in 2014 [6]. The production of carbapenemases (e.g., KPC, NDM, VIM, OXA-48-like) is the most common mechanism of resistance among K. pneumoniae isolates. Other mechanisms include alterations in outer membrane permeability, mediated by loss of porins and the upregulation of efflux systems [7].

The mortality rate of carbapenem-resistant Klebsiella pneumoniae (CRKp) infections in North America, South America, Europe, and Asia is reportedly 33.24%, 46.71%, 50.06%, and 44.82%, respectively [8]. Similarly, a study done in Shanghai, China showed that the 28-day mortality and in-hospital mortality rates of CRKp BSI patients were significantly higher than those of patients with carbapenem-susceptible K. pneumoniae (CSKp) BSIs (33.3% vs. 16%, p = 0.04; 42.4% vs. 24.6%, p = 0.005, respectively) [9]. Although CRKp is reportedly associated with prolonged hospitalization and mortality [8, 1012] because such patients typically receive inappropriate empiric therapy, other studies found no such relationship [1315].

There are various risk factors for CRKp BSI. A study conducted in a teaching hospital in Shanghai, China suggested that skin and soft tissue infection (odds ratio [OR] 26.63 and ICU-acquired infection (OR 5.82) was a risk factor for CRKp BSI [9]. multisite colonization (hazard ratio [HR] 13.73), ICU stay (HR 3.14) and previous BSI (HR 6.62) was associated with the development of CRKp BSI in colonized patients [16]. Primary liver disease and hepatitis C virus infection or hepatocellular cancer were significantly associated with development of CRKp in intensive care unit (ICU) patients after orthotopic liver transplantation [17]. Even no exposure independently predicted CRKp BSI in carriers of CRKp [18].

Similarly, several factors are reportedly associated with mortality related to K. pneumoniae BSI. The lung as the probable source of infection (OR 4.23) and a high Sequential Organ Failure Assessment (SOFA) score (OR 1.40) were strong prognostic factors for crude 28-day K. pneumoniae BSI mortality in a teaching hospital in Shanghai, China [9]. Septic shock (HR 3.86), acute respiratory failure (HR 2.32), inadequate initial antimicrobial therapy (HR 1.87) and carbapenem resistance by K. pneumoniae isolates (HR 1.85) were independently associated with mortality in onco-hematological patients [19]. In a univariate analysis, Acute Physiology and Chronic Health Evaluation (APACHE II) score, SOFA score, and CRKp BSI were predictive of ICU mortality after orthotopic liver transplantation [17].

It is generally accepted that CRKp BSIs are associated with high mortality, mostly because of the paucity of antimicrobials active against CRKp and the multiple comorbidities of patients [20]. Severe infection causes organ dysfunction and/or failure via complex mechanisms, including pathogenic microorganisms, an excessive inflammatory response, and immune dysfunction. However, antimicrobial resistance does not always lead to organ dysfunction and/or failure [21]. The immune system plays an important role in disease manifestations, with multiple contributing factors, some of which may not be accounted for by routinely collected data. At present, whether the systemic manifestations of infection and frequency of bacterial virulence genes differ between CRKp and CSKp BSI patients is unclear. Therefore, the objective of our study was to compare the prognosis and clinical characteristics of patients with CRKp and CSKp infections in the ICU, identify risk factors for the development of CRKp BSI and mortality of K. pneumoniae BSI, and assess the frequency of bacterial virulence genes in patients with CRKp and CSKp BSI.

Methods

Study design and patients

This retrospective case-control study was conducted at the First Affiliated Hospital of the Medical College, Zhejiang University, a 2500-bed tertiary-care teaching hospital, and included all adult patients with BSI caused by K. pneumoniae and hospitalized in the 30-bed medical ICU from January 1, 2013 to December 31, 2014.

The patients were identified using the records of the clinical microbiology laboratory. All patients with a positive blood culture for K. pneumoniae was included in the study. Infective symptoms and signs were compatible with systemic inflammatory response syndrome (SIRS; i.e., fever or hypothermia, respiratory rate > 20 breaths per minute, tachycardia >90 beats/min, and white blood cell count >11,000 ml or <4000/ml, using the 1999 criteria). If more than one episode occurred in the same patient, only the first episode was included in the study [22].

Cases with incomplete medical records were excluded from the study. From 2013, the identification and antimicrobial susceptibility testing of all blood K. pneumoniae isolates were performed using Vitek 2 panels (bioMerieux, France); isolates were stored at −80 °C [23]. Reserved strains were retrospectively tested for the presence of specific virulence genes.

The patients were divided into the CRKp and CSKp groups. Carbapenem resistance was defined as a minimum inhibitory concentration of ≥4 mg/L for meropenem or imipenem or ≥2 mg/L for ertapenem; other strains were defined as carbapenem-susceptible. Data interpretation was performed in accordance with the Clinical and Laboratory Standards Institute (CLSI) 2016 guidelines.

To identify risk factors for the development of CRKp BSI and m related ortality, the following data were recorded: demographics (sex, age), comorbidities, history of surgery, hospital or ICU admission in the last 30 days, use of steroids or immune modulators, antibiotic exposure history, and indwelling prosthetic material. In addition, for assessment of severe infection, APACHE II scores, liver function, kidney function, and inflammatory markers, at admission and at the time of positive blood culture, were recorded [17, 19].

The primary outcomes were crude survival rates at 7, 14, and 28 days. Secondary outcomes were current ICU stay duration, bacterial clearance rate, and duration of mechanical ventilation [24].

Multilocus sequence typing and pulsed-field gel electrophoresis

According to the multilocus sequence typing (MLST) scheme of K. pneumonia, seven conserved housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB, and tonB) were amplified and sequenced [25]. Pulsed-field gel electrophoresis (PFGE) was performed using XbaI (Dalian Takara Bio Inc., China), as described previously. To identify isolates associated with outbreaks, PFGE band patterns were interpreted according to the criteria proposed by Tenover et al. [26, 27].

Detection of virulence genes by polymerase chain reaction

The K1, K2, K5, K20, K54, and K57 capsular serotypes were detected by polymerase chain reaction (PCR), as described previously. Virulence genes (magA, rmpA, rmpA2, and allS) were detected by PCR using primers, as described previously. PCR products were interpreted and sequenced [23].

Statistical analysis

Statistical analyses were performed using SPSS software (ver. 18.0; SPSS Inc., USA). Continuous variables are presented as means ± SD and were evaluated by Student’s t-test or the Mann-Whitney U test, as appropriate. A chi-squared test or Fisher’s exact test was used for categorical variables, and multivariate analyses were performed using logistic regression models to identify independent risk factors for the outcome variables. All biologically plausible variables significant at p < 0.10 in univariate analysis were entered into a multivariate forward logistic regression analysis. A p value <0.05 was considered to indicate statistical significance.

Results

Demographics of the study population

Between January 1, 2013 and December 31, 2014, 48 patients had at least one episode of K. pneumoniae BSI in the ICU of our hospital. Thirty-three bloodstream isolates were included in this study; the others were excluded due to incomplete clinical information. The mean age in the CRKp and CSKp groups was 57.61 ± 14.78 and 62.71 ± 16.34 years, respectively (p = 0.306). Male patients accounted for 79% of the patients (56% in the CRKp group and 23% in the CSKp group, p = 0.502). To assess the frequency of bacterial virulence genes, 33 isolates (21 resistant and 12 susceptible) were obtained from 33 patients (17 and 4 male patients from the CRKp and CSKp groups, respectively [p = 0.357]). The mean age of these patients was 58.14 ± 15.16 and 65.58 ± 15.57 years, respectively (p = 0.190).

Clinical symptoms and prognostic factors of K. pneumoniae BSI

APACHEII score, peripheral blood leukocyte count, and C-reactive protein level were higher in the CSKp group than in the CRKp group at the time of bacteremia, albeit not significantly so. Many indexes showed the deteriorative tendencies in CSKp, including coagulation function, liver and kidney function, however only the static difference occurred in serum creatinine level (165.06 ± 127.01 in the CSKp group vs. 93.77 ± 84.35 μmol/L in the CRKp group, p = 0.039) (Table 1).
Table 1

Clinical symptoms of K. pneumoniae BSI

Variable

CSKp (n = 17)

CRKp (n = 31)

P

APACHEII score(mean ± SD)

18.18 ± 7.48

15.03 ± 6.38

0.089

WBC 10E9/L (mean ± SD)

14.24 ± 13.63

13.99 ± 9.66

0.497

leukocytes count (mean ± SD)

81.20 ± 14.60

88.02 ± 7.95

0.180

CRP(mg/l)(mean ± SD)

162.49 ± 118.07

113.74 ± 79.63

0.191

ALT (mean ± SD)

152.88 ± 399.23

49.84 ± 50.05

0.359

AST (mean ± SD)

490.82 ± 1655.64

49.63 ± 48.54

0.088

Total bilirubin (mean ± SD)

73.06 ± 142.17

62.68 ± 128.66

0.754

Direct bilirubin (mean ± SD)

43.29 ± 83.58

39.48 ± 86.63

0.779

PT (s) (mean ± SD)

17.71 ± 10.54

15.05 ± 5.27

0.439

Creatinine (mean ± SD)

165.06 ± 127.01

93.77 ± 84.35

0.039

Urea nitrogen (mean ± SD)

14.42 ± 9.88

14.40 ± 10.05

0.931

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, WBC white blood cell, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, PT prothrombin time

The prognostic factors of the CRKp and CSKp BSI patients are presented in Table 2. The duration of mechanical ventilation of the CRKp and CSKp groups was 18.50 ± 31.91 and 28.72 ± 31.06 days, respectively (p = 0.127). The current ICU stay duration was similar between the CRKp and CSKp groups (21.47 ± 33.67 vs. 31.74 ± 30.75 days, respectively [p = 0.073]). The bacterial clearance rate was 32% and 35% in the CRKp and CSKp groups, respectively (p = 0.718). The survival rate of the CRKp group was 74% at 7 days, 68% at 14 days, and 61% at 28 days, compared to 65% at 7 days, 59% at 14 days, and 47% at 28 days in the CSKp group (p = 0.489, 0.537, and 0.342, respectively).
Table 2

Clinical outcomes of K. pneumoniae BSI

Variable

CSKp (n = 17)

CRKp (n = 31)

P

Duration of mechanical ventilation (mean ± SD)(d)

18.50 ± 31.91

28.72 ± 31.06

0.127

Current ICU stay

21.47 ± 33.67

31.74 ± 30.75

0.073

Bacterial clearance rate

6(35%)

10(32%)

0.718

7-day survival rate

11(65%)

23(74%)

0.489

14-day survival rate

10(59%)

21(68%)

0.537

28-day survival rate

8(47%)

19(61%)

0.342

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, ICU intensive care unit

Risk factors for the development of CRKp BSI

In univariate analyses, development of CRKp BSI was significantly associated with central venous catheterization and an indwelling urinary catheter, but not with comorbidities (including diabetes mellitus, hypertension, coronary heart disease,chromic liver disease, chronic renal failure, solid organ tumor, history of surgery, prior healthcare-associated exposure, exposure to glucocorticoids and/or immunosuppressive drugs, trachea cannula or tracheotomy, an indwelling nasogastric tube, a drainage tube at multiple sites, and APACHE II score at admission). Hepatic and renal function at admission showed a trend towards being associated with the development of CRKp BSI. Although the majority of CRKp BSI patients had been exposed to antimicrobials before the positive culture, only exposure to tigecycline, imipenem and meropenem were included in the multivariate analysis of CRKp BSI (Table 3).
Table 3

Univariate analysis of risk factors for CRKp BSI

Variable

CSKp (n = 17)

CRKp (n = 31)

Univariate analysis

Adjusted OR

95% CI

P-value

Sex (male, n)

11(65%)

27(87%)

0.611

0.144—2.596

0.502

Age (y) (mean ± SD)

62.71 ± 16.34

57.61 ± 14.78

  

0.306

Co- morbidities

 Diabetes mellitus

5 (29%)

9 (29%)

0.982

0.268—3.602

0.978

 Hypertension

9 (53%)

15 (48%)

0.833

0.255—2.724

0.763

 Coronary heart disease

1 (6%)

3 (10%)

1.714

0.164—17.886

1

 Chronic liver disease

3(18%)

6(19%)

1.120

0.242–5.186

1

 Chronic renal failure

2 (12%)

4 (13%)

1.111

0.182—6.796

0.909

 Solid organ tumor

4 (24%)

7 (23%)

0.948

0.233—3.850

0.940

 HIV

0

0

NA

NA

NA

 Surgery in the past medical historya

3 (18%)

5 (16%)

0.897

0.186—4.322

0.893

 Prior healthcare-associated exposure

7 (41%)

9 (29%)

0.584

0.169—2.017

0.393

Prior medicine exposure

 Glucocorticoid

7 (41%)

13 (42%)

1.032

0.311—3.428

0.959

 Immunosuppressorb

1 (6%)

2 (6%)

1.103

0.093—13.135

1

Prior use of antimicrobials

 Penicillin

3 (18%)

10 (32%)

2.105

0.480—9.237

0.318

 Second cephalosporin

1 (6%)

4 (13%)

2.240

0.228—22.051

0.838

 extended-spectrum cephalosporins

7 (41%)

15 (48%)

1.224

0.351—4.269

0.750

 Aminoglycosides

1 (6%)

3 (10%)

1.615

0.153—17.016

1

 Quinolones

1 (6%)

3 (10%)

1.615

0.153—17.016

1

 Tigecycline

0

4 (13%)

0.625

0.492—0.795

0.613

 Imipenem

1 (6%)

11(39%)

8.556

0.984—74.408

0.064

 Meropenem

1 (6%)

12 (39%)

9.882

1.141—85.619

0.068

Ertapenem

0

0

NA

NA

NA

 Linezolid

1 (6%)

12 (39%)

9.882

1.141—85.619

0.068

 Glycopeptides Vancomycin

1 (6%)

8 (26%)

5.333

0.599—47.468

0.216

 Teicoplanin

1 (6%)

5 (16%)

2.917

0.309—27.560

0.333

Invasive procedure before

 Central venous catheterization

10(59%)

30 (97%)

21.000

2.294—192.225

0.003

 Trachea cannula

4(24%)

10 (32%)

1.548

0.401—5.971

0.525

 Tracheotomy

5(29%)

12 (39%)

1.516

0.426—5.393

0.519

 Urinary catheter

7(41%)

23 (74%)

4.107

1.168—14.436

0.024

 stomach tube

14(82%)

27 (87%)

1.446

0.283—7.384

0.656

 Intrathoracic drain

0(0)

4 (13%)

0.614

0.485—0.776

0.282

 Abdominal cavity drainage-tube

5(29%)

15 (48%)

2.250

0.639—7.923

0.202

 External ventricular drainage tube care

0(0)

1 (3%)

0.612

0.490—0.765

1

 Liver function on admission

5(35%)

3 (10%)

0.257

0.053—1.252

0.079

 Renal function on admission

7(41%)

4(13%)

0.275

0.071—1.070

0.055

 APACHE II score on admission

12.29 ± 7.32

9.45 ± 4.60

  

0.334

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, OR odds ratio, CI confidence interval, HIV human immunodeficiency virus, APACHE Acute Physiology and Chronic Health Evaluation

aHistory of surgery and non-invasive procedures, such as endoscopy or colonoscopy, are excluded from this category

bImmunosuppressors: Immunosuppressive drugs, immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of the immune system, including cytostatics, antibodies, drugs acting on immunophilins, etc. (https://en.wikipedia.org/wiki/Immunosuppressive_drug)

Variables significant at p < 0.10 in the univariate analyses were included in the multivariate analysis, and were as follows: an indwelling central venous catheter, indwelling urinary catheter, exposure to linezolid, imipenem and meropenem, and liver and kidney function at admission. In the multivariate analysis, central venous catheterization was the only independent factor for CRKp BSI. Exposure to imipenem and meropenem were likely related to CRKp BSI, but the association was not significant due to the small sample (Table 4).
Table 4

Multivariate analysis of risk factors for CRKp BSI

Variable

Adjusted OR

95% CI

P-value

Indwelling central venous catheters

14.343

1.063—193.444

0.045

Exposure to meropenem

11.968

0.756—69.720

0.086

Exposure to imipenem

7.258

0.945—151.497

0.055

Abbreviations: OR odds ratio, CI confidence interval

Risk factors for mortality of K. pneumoniae BSI patients

In univariate analyses, the mortality of K. pneumoniae BSI patients was significantly associated with the APACHE II score on the day of bacteremia, but not with CRKp. Liver failure on the day of bacteremia and trachea cannula showed a trend towards being associated with a higher mortality rate. Variables significant at p < 0.10 in the univariate analyses were included in the multivariate analysis. However, no factor was identified as being associated with the mortality of K. pneumoniae BSI patients in the multivariate analysis, likely due to the small sample size (Table 5).
Table 5

Univariate analysis of the 28-day mortality rate of K. pneumoniae BSI patients in the ICU

Variable

Died (n = 21)

Survived (n = 27)

Univariate analysis

P

OR

95% CI

Sex (male, n)

Age (y) (mean ± SD)

57.74 ± 16.63

61.57 ± 13.69

0.448

  

APACHE II score at admission

11.50 ± 5.53

10.07 ± 4.95

0.406

  

APACHE II score on the day of bacteremia

18.29 ± 7.36

14.48 ± 6.11

0.031

  

Liver failurea at admission

7

8

0.784

1.188

0.348—4.051

Kidney failureb at Admission

4

7

0.574

0.672

0.168—2.694

Liver failure on the day of bacteremia

11

7

0.06

3.143

0.933—10.584

Kidney failure on the day of bacteremia

6

6

0.614

1.400

0.377—5.195

Co-infection

14

20

0.575

0.700

0.2—2.445

CRKp

12(57.1%)

19(70.3%)

0.342

0.561

0.170—1.856

Diabetes mellitus

5(23.8%)

9(23.3%)

0.371

0.556

0.152—2.027

Hypertension

10(47.6%)

14(51.9%)

0.771

0.844

0.270—2.644

Coronary heart disease

2(9.5%)

2(7.4%)

0.792

1.316

0.170—10.208

Chronic renal failure

2(9.5%)

4(14.8%)

0.582

0.605

0.1—3.672

Solid organ tumor

4(19%)

7(25.9%)

0.574

0.672

0.168—2.694

Surgery in the past medical history

2(9.5%)

6(22.2%)

0.242

0.368

0.066—2.050

Prior healthcare-associated exposure

8(38.1%)

8(29.6%)

0.537

1.462

0.437—4.889

Glucocorticoid

8

12

0.658

0.769

0.240—2.460

Immunosuppressor

2(9.5%)

1(3.7%)

0.409

2.737

0.231—32.430

Central venous catheterization

17(81%)

23(85.2%)

0.696

0.739

0.161—3.383

Trachea cannula

9(42.9%)

5(18.5%)

0.066

3.3

0.899—12.108

Tracheotomy

6(27.3%)

11(40.7%)

0.325

0.545

0.162—1.833

Urinary catheter

13(61.9%)

17(16.9%)

0.940

0.956

0.295—3.102

Abdominal cavity drainage- tube

6(28.6%)

14(51.9%)

0.105

0.371

0.111—1.247

Stomach tube

18(85.7%)

23(85.2%)

0.959

1.043

0.305—0.593

Intrathoracic drain

0

4(14.8%)

0.121

0.523

0.394—0.693

External ventricular drainage tube care

1(4.7%)

0

0.438

0.426

0.305—0.593

Abbreviations: OR odds ratio, CI confidence interval, CRKp carbapenem-resistant Klebsiella pneumoniae

aLiver failure was defined as a serum bilirubin level of >3 mg/dl and/or prothrombin time (PT) of <50% on day 5 after surgery or thereafter; in patients with jaundice, it was defined as an increase in the serum bilirubin level or a PT < 50% on day 5 or thereafter [49]

bKidney failure was defined as a creatinine level of ≥2 mg/dl or requirement for dialysis [33]

Molecular characteristics of CRKp and CSKp BSI

The PFGE patterns revealed that the 33 isolates had different origins (Fig. 1). MLST revealed considerable clonal diversity; 18 sequence types (STs) were detected (Fig. 2), of which ST11 comprised the majority.
Fig. 1

Pulsed-field gel electrophoresis (PFGE) results. Pulsotypes of 33 K. pneumoniae blood isolates. The PFGE patterns revealed that the 33 isolates had different origins

Fig. 2

Multilocus sequence typing (MLST) results. Eighteen sequence types (STs) of 33 K. pneumoniae blood isolates. MLST indicated considerable clonal diversity; 18 STs were detected, of which ST11 comprised the majority

The CSKp isolates harbored the rmpA2, allS, K1, and magA virulence genes, while the CRKp isolates possessed rmpA2, magA, and K5, but not allS or K1. rmpA, K2, K20, K54, and K57 were not detected. The frequency of detection of allS and magA was higher in the CSKp group than in the CRKp group (allS p = 0.04; magA p = 0.047) (Table 6).
Table 6

Frequency rates of bacterial virulence genes in 33 isolates

Variable

CSKp (n = 12)

CRKp (n = 21)

P

rmpA2

3

4

0.686

Alls

3

0

0.04

K1

1

0

0.364

K5

0

1

1

magA

4

1

0.047

K1+ magA

1

0

0.364

rmpA2 + magA

1

0

0.364

alls + magA

1

0

0.364

rmpA

0

0

K2

0

0

K20

0

0

K54

0

0

K57

0

0

Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae

Discussion

CRKp BSI is a global public health problem that has been increasing in recent times, and is responsible for considerable morbidity [20, 28, 29]. The incidence of K. pneumoniae BSIs in ICU patients exceeds that of Escherichia coli BSIs [30, 31]. The mortality rate of critical patients with K. pneumoniae BSIs in the ICU was reported to rise up to 67.6% [30].

Population-based screening for K. pneumoniae bacteremia was conducted in the Calgary Health Region (population, 1.2 million) from 2000 to 2007. Dialysis, solid-organ transplantation, chronic liver disease, and cancer were risk factors for K. pneumoniae bacteremia [10]. CRE surveillance in Michigan healthcare facilities showed that cardiovascular disease, renal failure, and diabetes mellitus were the most frequently reported comorbidities, and risk factors for CRE included surgery within the previous 90 days, recent infection or colonization with a multidrug-resistant organism, and recent exposure to antimicrobials, particularly third- or fourth-generation cephalosporins [32]. The more frequent hospital contact associated with serious comorbidities may result in exposure to, and possibly infection by, nosocomial microorganisms. Moreover, severe chronic comorbidities were more frequent among patients with CRKp BSIs, but chronic comorbidities were not risk factors for CRKp BSI [33]. Similarly, in this study, comorbidities were not independent risk factors for CRKp BSI.

Glucocorticoids and immunosuppressors were not independent risk factors for CRKp BSI; however, previous studies reported different results. In one study, only prior carbapenem administration (p = 0.003), was significantly associated with CRKp infection, and another study revealed that the type of antibiotic used before infection—such as third-generation cephalosporins, macrolides and quinolones—was an independent risk factor for CRKp (p < 0.05) [11, 12]. Indeed, prior use of macrolides and antibiotic exposure for ≥14 days were the only factors independently associated with nosocomial CRKp bacteremia [33]. In another case-case control study, exposure to quinolones was not associated with CRKp infection, and colonization by CRKp and use of carbapenems were risk factors for infection with CRKp [34]. However, in our study, no antibiotic was a risk factor for CRKp BSI. Different in definitions, the duration of exposure to antibiotics, or different drug-treatment populations among these studies may account for the divergent findings.

In terms of invasive procedures, only an indwelling central venous catheter and urinary catheter were associated with CRKp BSI in univariate analyses. In the multivariate analysis, an indwelling central venous catheter was the only factor independently associated with CRKp BSI, partly consisted with the past studies [35, 36]. However, previous studies indicated that other variables, such as mechanical ventilation and a nasogastric tube, were related to CRKp BSI [3638].

Liver and kidney function indices at admission were higher in the CSKp group than in the CRKp group in this study, similar to some previous studies [15, 39]. However, reduced liver and kidney function was not associated with CRKp BSIs.

To improve outcomes, and where there is a need to avoid unnecessary antibiotics so as to reduce CRKp emergence, greater efforts should be made to ensure that initial appropriate antibiotic therapy is delivered to critically ill infected patients, and antibiotic de-escalation should be practiced to avoid unnecessary antibiotic exposure [40]. Moreover, control of the infection source is important for reducing the incidence of BSI. Central line (CL)-associated BSIs in ICUs result in increased morbidity and mortality, and are largely preventable; thus, preventive measures for catheter-related infection are important. Such measures can be applied at central line insertion and maintenance. For example, use of maximal sterile barrier precautions and/or avoiding the femoral vein were applied to reduce the risk of central venous catheter-related bloodstream infection. Moreover, use of central lines should be reduced wherever possible, such as by daily assessment of the need for a CL and timely removal of an unnecessary CL [41].

Infection-related mortality involves a number of factors, including host defense, virulence of the pathogen, source location and control, and the efficacy of available antimicrobials. A recent meta-analysis showed that patients with CRKp had a significantly higher mortality rate than those with CSKp (42.14 vs. 21.12, p < 0.001) [8]; this suggests that antimicrobial resistance is related to mortality. However, severe infections are not necessarily caused by drug-resistant bacteria, i.e., antimicrobial resistance is not linked with infection-induced organ dysfunction or failure, or with mortality, in critically ill patients. Therefore, the difference in clinical features and risk factors between CSKp and CRKp BSIs is intriguing.

In our study, the CSKp BSI patients had more severe clinical characteristics, such as higher APACHE II scores and lower alanine transaminase (AST) levels. Indeed, the serum creatinine level at the time of the positive culture was significantly higher in the CSKp group than in the CRKp group. However, CSKp BIS patients had only a trend towards a higher mortality rate. Therefore, although CS-Kp infection can lead to worse clinical symptoms, the mortality rate is similar between the two groups, despite there being fewer therapeutic options for CRKp BSI.

The risk factors for mortality due to CSKp and CRKp infection were evaluated in this study. The mortality of K. pneumoniae BSI patients was associated with a higher APACHE II score, liver failure, and trachea cannula on the day of bacteremia, but not with carbapenem resistance. In another study, multivariate analyses revealed that carbapenem resistance was not a risk factor for mortality due to K. pneumoniae bacteremia [33]. The mortality rate of CRKp patients was significantly higher than that of CSKp patients in that study, which contradicts our findings and those of a study conducted in Israel in 2012 [42]. The risk factors for mortality due to K. pneumoniae BSI vary among studies, and include bedridden status, chronic liver disease, Charlson comorbidity index ≥5, mechanical ventilation, hemodialysis [33], and Pitt bacteremia score [42].

PFGE and MLST revealed that the isolates had considerable clonality; the 33 isolates were of different origins. No suspected outbreaks occurred during the study period. We assessed the frequency of 10 virulence genes in the CSKp and CRKp BSI isolates. magA is involved in the production of the K1 capsule, which is an important virulence factor [43]. A previous study confirmed local emergence of K. pneumoniae invasive syndrome and implicated magA and rmpA in its pathogenesis [44]. A number of putative virulence factors, including magA and rmpA, are associated with hypermucoviscous K. pneumoniae (hvKP), which can cause serious infections [45, 46]. Alarmingly, multidrug-resistant, including carbapenem-resistant hvKP isolates have emerged [23, 47, 48]; thus, we assessed the frequency rates of various virulence genes in the CRKp and CSKp groups. The frequency rates of allS and magA were higher in the CSKp group than in the CRKp group, despite the small number of subjects. Therefore, further studies of virulence genes, possibly using whole-genome sequencing (which is becoming less costly and more rapid) and involving larger populations, are warranted.

Our study had several limitations. First, relatively few patients were enrolled, which hampered the multivariate analysis and ability to draw firm conclusions. Second, some K. pneumoniae isolates were not stored. Third, the therapeutic regimen for K. pneumoniae BSI was not taken into consideration. Fourth, in the ICU setting, a heterogeneous population can limit the statistical analysis. Fifth, the role of the immune system was not analyzed. Despite these limitations, however, we identified several differences between the CRKp and CSKp groups, and explored the impact of carbapenem resistance and bacterial virulence genes on the outcomes of patients with K. pneumoniae BSIs.These data can lay the groundwork for future research in this field.

Conclusions

An indwelling central venous catheter is a risk factor for CRKp BIS. Liver and kidney function at admission were lower in the CSKp group than in the CRKp group in this study. The mortality rate and frequency of bacterial virulence genes were similar between the CSKp and CRKp groups. Mortality due to K. pneumoniae BSI was not related to carbapenem resistance in univariate analysis. Further study is required to verify the correlation between CRKp-mortality mortality and the virulence genes of K. pneumoniae isolates.

Abbreviations

ALT: 

Alanine transaminase

APACHE II: 

Acute Physiology and Chronic Health Evaluation

AST: 

Aspartate transaminase

BSIs: 

Bloodstream infections

CI: 

Confidence interval

CL: 

Central line

CLSI: 

Clinical and laboratory standards institute

CRE: 

Carbapenem-resistant Enterobacteriaceae

CRKp: 

Carbapenem-resistant K. pneumoniae

CRP: 

C-reactive protein

CSKp: 

Carbapenem-susceptible K. pneumoniae

HIV: 

Human immunodeficiency virus

HR: 

Hazard ratio

hvKP: 

Hypermucoviscous K. pneumoniae

ICU: 

Intensive care unit

MLST: 

Multilocus sequence typing

OR: 

Odds ratio

PCR: 

Polymerase chain reaction

PFGE: 

Pulsed-field gel electrophoresis

PT: 

Prothrombin time

SIRS: 

Systemic inflammatory response syndrome

SOFA: 

Sequential organ failure assessment

ST: 

Sequence typing

UTIs: 

Urinary tract infections

UTIs: 

Urinary tract infections

WBC: 

White blood cell

Declarations

Acknowledgments

Not applicable.

Funding

No funding.

Availability of data and materials

The data used and/or analyzed in this study are available from the corresponding author on reasonable request.

Authors’ contributions

XZ contributed to the writing of the manuscript; JFW analyzed bacterial virulence genes; WX analyzed and interpreted the clinical data; JX analyzed the antimicrobial susceptibility results; JH performed the statistical analysis; all authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the First Affiliated Hospital, College of Medicine, Zhejiang University. This research was conducted in compliance with the tenets of the Helsinki Declaration.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Intensive Care Unit, The First Affiliated Hospital, College of Medicine, Zhejiang University
(2)
Department of Respiratory Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou
(3)
Intensive Care Unit, Hospital of Zhejiang General Corps of Armed Police Forces

References

  1. Broberg CA, Palacios M, Miller VL. Klebsiella: a long way to go towards understanding this enigmatic jet-setter. F1000prime reports. 2014;6:64.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Siu LK, Yeh KM, Lin JC, Fung CP, Chang FY. Klebsiella pneumoniae liver abscess: a new invasive syndrome. The Lancet Infectious diseases.2012;12:881–7.Google Scholar
  3. Hansen DS, Gottschau A, Kolmos HJ. Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia Coli bacteraemia as control. J Hosp Infect. 1998;38:119–32.View ArticlePubMedGoogle Scholar
  4. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella Pneumoniae: a clinical perspective. Expert Rev Anti-Infect Ther. 2012;10:1393–404.View ArticlePubMedGoogle Scholar
  5. Yang Y, Chen J, Lin D, Xu X, Cheng J, Sun C. Prevalence and drug resistance characteristics of carbapenem-resistant Enterobacteriaceae in Hangzhou, China. Front Med. 2017; 10.1007/s11684-017-0529-4.
  6. Xu A, Zhuo C, Su DH, Hu FP, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, Sun ZY, Chen ZJ, Ni YX, Sun JY, Hu ZD, Li J, Zhang ZX, Ji P, Wang CQ, Wang AM, Yang Q, Xu YH, Shen JL, Shan B, Du Y, Zhang H, Kong J, Wei LH, Wu L, Xie Y, Kang M, Hu YJ, Ai XM, Yu YS, Lin J, Huang WX, Jia B, Chu YZ, Tian SF, Han YQ, Guo SF. Changing susceptibility of Klebsiella strains in hospitals across China:data from the CHINET antimicrobial resistance surveillance program, 2005-2014. Chin J Infect Chemother. 2016;16:267–74.Google Scholar
  7. Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella Pneumoniae, a key pathogen set for global Nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873–84.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella Pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16:18.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Tian L, Tan R, Chen Y, Sun J, Liu J, Qu H, Wang X. Epidemiology of Klebsiella Pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control. 2016;5:48.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Meatherall BL, Gregson D, Ross T, Pitout JD, Laupland KB. Incidence, risk factors, and outcomes of Klebsiella Pneumoniae bacteremia. Am J Med. 2009;122:866–73.View ArticlePubMedGoogle Scholar
  11. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella Pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–33.View ArticlePubMedGoogle Scholar
  12. Gallagher JC, Kuriakose S, Haynes K, Axelrod P. Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella Pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2014;58:5732–5.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, Maraki S, Samonis G, Michalopoulos A. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;6.Google Scholar
  14. Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella Pneumoniae bacteremia at a university hospital in northern Taiwan: a matched case-control study. J Microbiol Immunol Infect. 2012;45:113–9.View ArticlePubMedGoogle Scholar
  15. Ny P, Nieberg P, Wong-Beringer A. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella Pneumoniae infections. Am J Infect Control. 2015;43:1076–80.View ArticlePubMedGoogle Scholar
  16. Giacobbe DR, Del Bono V, Bruzzi P, Corcione S, Giannella M, Marchese A, Magnasco L, Maraolo AE, Pagani N, Saffioti C, Ambretti S, Cardellino CS, Coppo E, De Rosa FG, Viale P, Viscoli C, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella Pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study. Eur J Clin Microbiol Infect Dis. 2017;36:663–9.View ArticlePubMedGoogle Scholar
  17. Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, Piperidou M, Orphanou A, Passakiotou M, Imvrios G, Fouzas I, Papanikolaou V, Gritsi-Gerogianni N. Bloodstream infections caused by carbapenemase-producing Klebsiella Pneumoniae among intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact of resistance on outcomes. Transplant Proc. 2014;46:3216–8.View ArticlePubMedGoogle Scholar
  18. Amit S, Mishali H, Kotlovsky T, Schwaber MJ, Carmeli Y. Bloodstream infections among carriers of carbapenem-resistant Klebsiella Pneumoniae: etiology, incidence and predictors. Clin Microbiol Infec. 2015;21:30–4.View ArticleGoogle Scholar
  19. Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Perriello V, Busca A, Aversa F, Fanci R, Melillo L, Lessi F, Del Principe MI, Cattaneo C, Tumbarello M. HaematologicMalignancies associated bloodstream infections surveillance (HEMABIS) registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne(SEIFEM) group, Italy. Bloodstream infections caused by Klebsiella Pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91:1076–81.View ArticlePubMedGoogle Scholar
  20. Cristina ML, Alicino C, Sartini M, Faccio V, Spagnolo AM, Del Bono V, Cassola G, De Mite AM, Crisalli MP, Ottria G, Schinca E, Lo Pinto G, Bottaro LC, Viscoli C, Orsi A, Giacobbe DR, Icardi G, Genoan Klebsiella pneumoniae research group. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella Pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. J Infect Public Health. 2017; 10.1016/j.jiph.2017.06.003.
  21. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. Comparison of community- and health care-associated methicillin-resistant Staphylococcus Aureus infection. JAMA. 2003;290:2976–84.View ArticlePubMedGoogle Scholar
  22. Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella Pneumoniae infections in the intensive care unit. J Infect. 2015;70:592–9.View ArticlePubMedGoogle Scholar
  23. Yao B, Xiao X, Wang F, Zhou L, Zhang X, Zhang J. Clinical and molecular characteristics of multi-clone carbapenem-resistant hypervirulent (hypermucoviscous) Klebsiella Pneumoniae isolates in a tertiary hospital in Beijing, China. Int J Infect Dis. 2015;37:107–12.View ArticlePubMedGoogle Scholar
  24. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter Baumannii and Klebsiella Pneumoniae. J Antimicrob Chemother. 2008;62 Suppl 1:i29–40.View ArticlePubMedGoogle Scholar
  25. Li W, Sun G, Yu Y, Li N, Chen M, Jin R, Jiao Y, Wu H. Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella Pneumoniae isolates in China. Clin Infect Dis. 2014;58:225–32.View ArticlePubMedGoogle Scholar
  26. Duck WM, Steward CD, Banerjee SN, McGowan JE Jr, Tenover FC. Optimization of computer software settings improves accuracy of pulsed-field gel electrophoresis macrorestriction fragment pattern analysis. J Clin Microbiol. 2003;41:3035–42.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Endimiani A, Depasquale JM, Forero S, Perez F, Hujer AM, Roberts-Pollack D, Fiorella PD, Pickens N, Kitchel B, Casiano-Colón AE, Tenover FC, Bonomo RA. Emergence of blaKPC-containing Klebsiella Pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother. 2009;64:1102–10.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Cristina ML, Sartini M, Ottria G, Schinca E, Cenderello N, Crisalli MP, Fabbri P, Lo Pinto G, Usiglio D, Spagnolo AM. Epidemiology and biomolecular characterization of carbapenem-resistant klebsiella pneumoniae in an Italian hospital. J Prev Med Hyg. 2016;57:E149–E56.Google Scholar
  29. Raz-Pasteur A, Hussein K, Finkelstein R, Ullmann Y, Egozi D. Blood stream infections (BSI) in severe burn patients--early and late BSI: a 9-year study. Burns. 2013;39:636–42.Google Scholar
  30. Delle Rose D, Sordillo P, Gini S, Cerva C, Boros S, Rezza G, Meledandri M, Gallo MT, Prignano G, Caccese R, D'Ambrosio M, Citterio G, Rocco M, Leonardis F, Natoli S, Fontana C, Favaro M, Celeste MG, Franci T, Testore GP, Andreoni M, Sarmati L. Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals. Am J Infect Control. 2015;43:1178–83.Google Scholar
  31. Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930–45.Google Scholar
  32. Brennan BM, Coyle JR, Marchaim D, Pogue JM, Boehme M, Finks J, Malani AN, VerLee KE, Buckley BO, Mollon N, Sundin DR, Washer LL, Kaye KS. Statewide surveillance of carbapenem-resistant enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol. 2014;35:342–9.Google Scholar
  33. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, Kassis I. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013;83:307–13.Google Scholar
  34. Gomez Rueda V, Zuleta Tobon JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colombia medica (Cali, Colombia). 2014;45:54–60.Google Scholar
  35. Diaz A, Ortiz DC, Trujillo M, Garces C, Jaimes F, Restrepo AV. Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae infections in Ill and colonized children in Colombia. Pediatr Infect Dis J. 2016;35:237–41.Google Scholar
  36. Akgul F, Bozkurt I, Sunbul M, Esen S, Leblebicioglu H. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: case control study. Pathog Global Health. 2016;110:321–5.Google Scholar
  37. Candevir Ulu A, Kurtaran B, Inal AS, Komur S, Kibar F, Yapici Cicekdemir H, Bozkurt S, Gürel D, Kılıç F, Yaman A, Aksu HS, Taşova Y. Risk factors of carbapenem-resistant Klebsiella pneumoniae infection: a serious threat in ICUs. Med Sci Monit. 2015;21:219–24.Google Scholar
  38. Mills JP, Talati NJ, Alby K, Han JH. The epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization and infection among long-term acute care hospital residents. Infect Control Hosp Epidemiol. 2016;37:55–60.Google Scholar
  39. Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infec. 2015;70:592–9.Google Scholar
  40. Markley JD, Bernard S, Bearman G, Stevens MP. De-escalating antibiotic use in the inpatient setting: strategies, controversies, and challenges. Curr Infect Dis Rep. 2017;19.Google Scholar
  41. Valencia C, Hammami N, Agodi A, Lepape A, Herrejon EP, Blot S, et al. Poor adherence to guidelines for preventing central line-associated bloodstream infections (CLABSI): results of a worldwide survey. Antimicrob Resist Infect. 2016;5:49.Google Scholar
  42. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infec. 2012;18:54–60.Google Scholar
  43. Yeh KM, Chang FY, Fung CP, Lin JC, Siu LK. magA is not a specific virulence gene for Klebsiella pneumoniae strains causing liver abscess but is part of the capsular polysaccharide gene cluster of K. pneumoniae serotype K1. J Med Microbiol. 2006;55:803–4.Google Scholar
  44. Chang L, Bastian I, Warner M. Survey of Klebsiella pneumoniae bacteraemia in two South Australian hospitals and detection of hypermucoviscous phenotype and magA/rmpA genotypes in K. pneumoniae isolates. Infection. 2013;41:559–63.Google Scholar
  45. Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med. 2004;199:697–705.Google Scholar
  46. Yu WL, Ko WC, Cheng KC, Lee HC, Ke DS, Lee CC, Fung CP, Chuang YC. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 2006;42:1351–8.Google Scholar
  47. Yang Z, Liu W, Cui Q, Niu W, Li H, Zhao X, Wei X, Wang X, Huang S, Dong D, Lu S, Bai C, Li Y, Huang L, Yuan J. Prevalence and detection of Stenotrophomonas maltophilia carrying metallo-beta-lactamase blaL1 in Beijing, China. Front Microbiol. 2014;5:692.Google Scholar
  48. Zhang Y, Zeng J, Liu W, Zhao F, Hu Z, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Li S, Cao B, Wang H. Emergence of a hypervirulent carbapenem-resistant Klebsiella pneumoniae isolate from clinical infections in China. J Infect. 2015;71:553–60.Google Scholar
  49. Capussotti L, Vigano L, Giuliante F, Ferrero A, Giovannini I, Nuzzo G. Liver dysfunction and sepsis determine operative mortality after liver resection. Br J Surg. 2009;96:88–94.Google Scholar

Copyright

© The Author(s). 2017

Advertisement